Enlivex Ltd
1BT
Company Profile
Business description
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Contact
14 Einstein Street
Weizmann Science Park
Ness Ziona7403618
ISRT: +972 86328500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
34
Stocks News & Analysis
stocks
CSL’s latest result suggests the worst may be over
Relief replaces disappointment but can growth return?
stocks
ASX listed pharma boosted by weight loss drugs
GLP-1 momentum drives earnings for narrow moat share.
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,271.40 | 6.30 | 0.07% |
| CAC 40 | 8,388.13 | 13.05 | -0.16% |
| DAX 40 | 26,338.03 | 231.96 | -0.87% |
| Dow JONES (US) | 53,205.36 | 354.63 | -0.66% |
| FTSE 100 | 10,824.26 | 31.72 | 0.29% |
| HKSE | 25,566.99 | 17.80 | -0.07% |
| NASDAQ | 26,285.02 | 117.40 | -0.44% |
| Nikkei 225 | 66,311.93 | 93.63 | -0.14% |
| NZX 50 Index | 13,917.30 | 149.12 | 1.08% |
| S&P 500 | 7,676.40 | 35.36 | -0.46% |
| S&P/ASX 200 | 9,076.00 | 10.40 | 0.11% |
| SSE Composite Index | 3,986.30 | 34.12 | 0.86% |